Bimagrumab: Risks & Legal Status
Important safety information, risks, and regulatory status
📌TL;DR
- •5 risk categories identified
- •0 high-severity risks
- •Legal status varies by country (3 countries listed)
Risk Assessment
Bimagrumab is not approved by any regulatory agency worldwide. It is available only within clinical trials. All efficacy data is from Phase 2 studies, which are not sufficient for regulatory approval. No Phase 3 registration trial has been completed for any indication.
Bimagrumab blocks signaling by multiple TGF-beta superfamily ligands beyond myostatin, including activin A, GDF-11, and potentially BMP-9/10. These pathways are involved in vascular homeostasis, reproductive biology, bone metabolism, and immune regulation. Long-term consequences of broad pathway blockade are not fully characterized.
Despite Eli Lilly's $1.925 billion acquisition of Versanis Bio in 2023, one key combination trial (bimagrumab + tirzepatide in T2D) was terminated in 2025. The path to regulatory approval remains unclear, and commercial development may face additional setbacks.
Bimagrumab requires intravenous infusion at clinical sites, creating access barriers and compliance challenges compared to subcutaneous self-injection. This limits practical utility for chronic conditions requiring long-term treatment.
The RESILIENT trial demonstrated that bimagrumab increases lean mass but this did not translate to improved physical function in IBM patients. This raises questions about whether body composition improvements alone are clinically meaningful outcomes.
⚠️Important Warnings
- •INVESTIGATIONAL DRUG: Bimagrumab is not approved for any clinical use. It is available only to enrolled participants in clinical trials and cannot be purchased or prescribed.
- •NOT A PEPTIDE: Bimagrumab is a full-size monoclonal antibody (~145 kDa) that cannot be obtained from peptide suppliers or compounding pharmacies. Products marketed as "bimagrumab peptide" are not legitimate.
- •The RESILIENT trial failure in IBM demonstrates that increased lean mass does not necessarily translate to improved physical function. Body composition changes should not be assumed to be clinically meaningful without functional endpoint data.
- •One Eli Lilly combination trial (bimagrumab + tirzepatide in T2D/obesity) was terminated in 2025 for strategic reasons. The overall development program faces uncertainty.
- •Long-term safety of chronic ActRII blockade beyond 52 weeks has not been established. Effects on reproductive hormones, vascular biology, and bone metabolism require further study.
Legal Status by Country
| Country | Status | Notes |
|---|---|---|
| United States | Investigational | Not FDA-approved for any indication. Available only within clinical trials. Held by Eli Lilly following acquisition of Versanis Bio. Multiple IND applications on file for various indications. |
| European Union | Investigational | Not EMA-approved. Clinical trials conducted at European sites as part of global studies. No marketing authorization application submitted. |
| International | Investigational | Not approved in any jurisdiction. Clinical trials conducted globally (RESILIENT at 38 sites across Australia, Europe, Japan, USA). Only accessible through clinical trial enrollment. |
Community Risk Discussions
See how the community discusses and manages these risks in practice.
Based on 40+ community reports
View community protocolsCritical Safety Information#
Bimagrumab is an investigational monoclonal antibody that has not been approved by any regulatory agency. While it has a relatively well-characterized safety profile from multiple clinical trials, it remains unavailable outside of clinical trial enrollment.
Risk Assessment#
Not Yet Approved#
Despite extensive clinical testing (including trials with 40-507 participants), bimagrumab has not completed a successful Phase 3 registration trial:
- The RESILIENT Phase 2b/3 trial in IBM failed its primary endpoint
- Obesity/body composition data is Phase 2 only (BELIEVE is Phase 2b)
- No FDA, EMA, or other regulatory approval
- No New Drug Application or Marketing Authorization Application filed
TGF-Beta Pathway Risks#
Bimagrumab blocks multiple TGF-beta superfamily ligands at the receptor level:
| Ligand | Pathway Role | Risk of Chronic Blockade |
|---|---|---|
| Activin A | Reproductive biology, FSH regulation | Potential fertility effects |
| BMP-9/10 | Vascular endothelial homeostasis | Potential vascular effects |
| GDF-11 | Aging, tissue homeostasis | Unknown long-term effects |
| Myostatin | Muscle mass regulation | Intended therapeutic effect |
The experience with ACE-031 (ActRIIB-Fc fusion, discontinued due to bleeding and telangiectasia) underscores that broad activin receptor pathway blockade can have clinically significant vascular side effects.
Development Uncertainty#
The bimagrumab development timeline reflects both promise and uncertainty:
| Year | Event |
|---|---|
| ~2013 | Novartis initiates clinical development |
| 2019 | RESILIENT IBM trial fails primary endpoint |
| ~2021 | Novartis licenses to Versanis Bio (obesity pivot) |
| 2021 | Positive Phase 2 obesity/T2D results published |
| 2023 | Eli Lilly acquires Versanis for up to $1.925B |
| 2025 | Lilly terminates T2D combination trial |
| 2026 | Obesity-only combination trial continues |
Not Available as Research Peptide#
A unique risk factor for consumers is the misconception that bimagrumab can be obtained like other research peptides:
- Bimagrumab is a ~145 kDa monoclonal antibody requiring mammalian cell production
- It cannot be synthesized by peptide synthesis companies
- No legitimate research chemical supplier offers bimagrumab
- Any product marketed as "bimagrumab peptide" is fraudulent
- The only access is through clinical trial enrollment
Regulatory Status#
| Jurisdiction | Status | Access |
|---|---|---|
| United States | Investigational (IND) | Clinical trials only |
| European Union | Investigational | Clinical trials only |
| Japan | Investigational | Clinical trials only |
| International | Not approved | No commercial availability |
Risk Summary#
| Risk Category | Severity | Basis |
|---|---|---|
| Not approved/investigational | Moderate | Phase 2 data only; no registration trial |
| TGF-beta off-target effects | Moderate | ACE-031 precedent; theoretical concerns |
| Development uncertainty | Moderate | Trial termination; unclear commercial path |
| IV administration barrier | Low-Moderate | Requires clinic visits for infusion |
| Functional vs composition gap | Moderate | IBM RESILIENT failure |
| Consumer fraud risk | Moderate | Cannot be purchased; fake products possible |
Recommendations#
Bimagrumab is only accessible through clinical trial enrollment. Individuals interested in bimagrumab should monitor ClinicalTrials.gov for active recruitment. The promising body composition data from Phase 2 studies requires Phase 3 confirmation before clinical utility can be established.
Related Reading#
Frequently Asked Questions About Bimagrumab
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.